ArticleAnnals of clinical and translational neurology2025
Effects of Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs on Acute Intracerebral Hemorrhage.
Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic strategies in intracerebral hemorrhage: from hematoma stabilization to alleviating secondary brain injury.Research and practice in thrombosis and haemostasis · 2026Review
- Effectiveness of Pre-Emptive Incision-Site Infiltration with Ropivacaine Combined with Triamcinolone Acetonide versus Ropivacaine for Post-Craniotomy Pain in Adults: A Prospective Randomized Controlled Trial.Journal of pain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveDespite celecoxib, a cyclooxygenase-2 inhibitor, promoting functional recovery from intracerebral hemorrhage (ICH) by reducing inflammation-mediated perihematomal edema in rat models, the evidence of its effects on patient outcomes remains limited. As nonsteroidal anti-inflammatory drugs (NSAIDs) alleviate inflammation by inhibiting cyclooxygenase-2, this study aimed to assess the impact of non-aspirin NSAIDs on ICH outcomes.
methodsPatients with acute ICH admitted to our hospital between January 2015 and December 2020 were prospectively enrolled and retrospectively categorized based on pre- or post-ICH use of non-aspirin NSAIDs. Outcomes were assessed using the modified Rankin Scale (mRS) score at 3 months, survival at 1 year, and mortality at long-term follow-up.
resultsAmong 976 patients with acute ICH, 2.0% and 15.0% were non-aspirin NSAID users before and after ICH, respectively. Post-ICH non-aspirin NSAID use was associated with a reduced 1-year mortality risk (adjusted odds ratio [aOR] 0.30, p = 0.001) and long-term mortality risk (adjusted hazard ratio 0.56, p = 0.043), but not good functional outcomes (mRS 0-2) (aOR 0.98, p = 0.940). In the subgroup analyses, post-ICH use might be linked to good functional outcomes in patients with lobar hemorrhage or in those without surgical intervention. Pre-ICH non-aspirin NSAID use was not associated with these outcomes in the overall population, but it might be linked to increased mortality in subgroups with lobar hemorrhage, cerebral amyloid angiopathy, hyperlipidemia, or without intraventricular hemorrhage.
interpretationThe post-ICH use of non-aspirin NSAIDs reduced mortality. Future studies are warranted to identify specific non-aspirin NSAID regimens that can significantly improve the outcomes of patients with ICH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.